We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Universal Diabetes Screening Recommended During Pregnancy

By LabMedica International staff writers
Posted on 29 Jan 2014
New US federal recommendations suggest that all women should be screened for gestational diabetes at 24 weeks of pregnancy, even if they have no symptoms.

The B-level recommendation from the US Preventive Services Task Force (USPSTF; Rockville, MD, USA) aligns with that of several other organizations, including the American Association of Clinical Endocrinologists, the American Diabetes Association (ADA, Alexandria, VA, USA), and the American College of Obstetricians and Gynecologists (ACOG).

The USPSTF recommends testing with a 2-hour, 50 gram oral glucose challenge test (OGCT) between 24–28 weeks of gestation. If patients hit or exceed a threshold of 130 mg/dL, they should follow-up with the 2-hour, 100 gram oral glucose tolerance test (OGTT). Other options for screening include a fasting plasma glucose or screening based on other risk factors, but the task force claims there is limited evidence on these alternative screening approaches. The task force concluded that there is insufficient evidence to assess risk and benefits of screening before 24 weeks' gestation.

The Task Force stated that screening and treatment lower the risk of preeclampsia, a condition in pregnant women characterized by high blood pressure and high levels of protein in the urine, which can result in life-threatening seizures. Treating diabetes during pregnancy can also prevent babies from growing larger than normal (macrosomia), a condition that can lead to birth injuries. The USPSTF recommendations were published on January 14, 2014, in the Annals of Internal Medicine.

“Diabetes that begins during pregnancy can cause serious health problems for expectant mothers and their babies,” said USPSTF chair Virginia Moyer, MD, MPH. “The good news is that screening all women after 24 weeks of pregnancy is simple, and can result in better health outcomes for both the mother and the baby.”

“All women should talk to their doctors or nurses about actions they can take before becoming pregnant to improve their health,” added Dr. Moyer, “including maintaining a healthy weight, quitting smoking, and managing any chronic conditions.”

In the OGTT, a standard dose of glucose is ingested orally and blood levels are checked two hours later. Fasting plasma glucose (measured before the OGTT begins) should be below 110 mg/dL. Fasting levels of 110–125 mg/dL are indicative of impaired fasting glycemia, while fasting levels repeatedly at or above 126 mg/dL are diagnostic of diabetes. A 2-hour OGTT glucose level below 140 mg/dL is normal, whereas higher glucose levels indicate hyperglycemia. Blood plasma glucose of 140–200 mg/dL indicate impaired glucose tolerance, and levels above 200 mg/dL at 2 hours confirms a diagnosis of diabetes.

Related Links:

US Preventive Services Task Force
American Diabetes Association



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.